Initiated at Mayo Clinic, the human clinical trial will evaluate whether Elysium’s proprietary nicotinamide riboside (NR-E) can augment bone, skeletal muscle, and metabolic functions and structure in aging. The study is complete and pending publication. ClinicalTrials.gov Identifier: NCT03818802
Related Articles
-
TIME-ZZZ
The Translational Initiative to Map Epigenetics in Sleep (TIME-ZZZ) is a longitudinal, prospective research study that aims to advance our understanding of the interplay between sleep, mental health, and biological aging. All Index users are eligible to enroll. The study can be found on www.clinicaltrials.gov under the identifier NCT06333301. -
NADAPT
Initiated at Haukeland University Hospital, this human clinical trial is evaluating the efficacy of NAD replenishment therapy with NR in delaying disability progression and amelioration of symptoms in patients with atypical parkinsonian syndromes. The estimated study completion date is December 2028. ClinicalTrials.gov Identifier: NCT06162013 -
Progressive MS
Initiated at Haukeland University Hospital, this human clinical trial is evaluating the safety and efficacy of NR on slowing disability progression in patients with progressive multiple sclerosis. The estimated study completion date is December 2027. ClinicalTrials.gov Identifier: NCT05740722